Progress toward long-term survivors of glioblastoma
Mayo clinic proceedings, 2019•Elsevier
Objective To identify the frequency and characteristics of long-term survivors of
glioblastoma. Patients and Methods Using all cases of glioblastoma with histopathological
confirmation in the National Cancer Database from January 1, 2004, through December 31,
2009, clinical, institutional, and treatment-related factors were evaluated with multivariable
logistic regression models so as to elucidate factors independently associated with higher
than 5-year overall survival after diagnosis. Results A total of 48,652 patients met the …
glioblastoma. Patients and Methods Using all cases of glioblastoma with histopathological
confirmation in the National Cancer Database from January 1, 2004, through December 31,
2009, clinical, institutional, and treatment-related factors were evaluated with multivariable
logistic regression models so as to elucidate factors independently associated with higher
than 5-year overall survival after diagnosis. Results A total of 48,652 patients met the …
Objective
To identify the frequency and characteristics of long-term survivors of glioblastoma.
Patients and Methods
Using all cases of glioblastoma with histopathological confirmation in the National Cancer Database from January 1, 2004, through December 31, 2009, clinical, institutional, and treatment-related factors were evaluated with multivariable logistic regression models so as to elucidate factors independently associated with higher than 5-year overall survival after diagnosis.
Results
A total of 48,652 patients met the inclusion criteria, with 2249 (4.6%) achieving 5-year survival. Factors associated with odds of improved 5-year overall survival in multivariable analysis were younger age, female sex, less medical comorbidities, nonwhite race, highest median income quartile, left-sided tumors and tumors outside the brainstem, and treatment with radiotherapy (P<.05 for all). The percentage of patients surviving 5 years remained relatively unchanged over the 6-year study period (P=.97).
Conclusion
Despite improvements in median and short-term overall survival shown in recent large clinical trials for glioblastoma, the percentage of patients with glioblastoma achieving 5-year overall survival remains low. This observation calls for the development of practice-redefining therapies and justifies the increased application of radical novel and experimental treatment paradigms for all patients with glioblastoma.
Elsevier